Enliven Therapeutics announced plans to start the Phase 3 pivotal trial of its chronic myeloid leukemia drug ELVN-001 in the second half of 2026, following positive Phase 1 data. The company highlights ELVN-001 as a potentially best-in-class treatment targeting the BCR::ABL gene fusion in CML patients. Enliven reported a net loss of $23.6 million in Q1 2026 but maintains a strong cash reserve of $452 million, expected to fund operations into mid-2029. Key upcoming milestones include additional Phase 1 data presentations and regulatory discussions with the FDA on trial design and dosing.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
